Skip to main content

Table 1 Overview of inclusion and exclusion criteria in the BLMs4BU study

From: Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin

Inclusion criteria

Patients must fulfil the following criteria:

 •Age of ≥ 5 years and adults ≤ 70 years

 •New clinical diagnosis of BU (all categories: I, II, and III)

 •Normal ECG

Exclusion criteria

Patients with any of the following criteria are not eligible:

 •Children < 5 years and adults > 70 years

 •Children in foster care

 •Patients weighing less than 11 kg 

 •Pregnancy positive (urine test: beta-HCG positive)

 •Previous treatment of Buruli ulcer, tuberculosis, or leprosy with at least one of the study drugs

 •Patients with diagnosed leprosy or tuberculosis disease

 •Hypersensitivity to at least one of the study drugs or to any of the excipients

 •History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem, or monobactam)

 •History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid or rifampicin

 •Patients with history of treatment with macrolide or quinolone antibiotics, anti-tuberculosis medication, or immuno-modulatory drugs including corticosteroids within 1 month

 •Patients currently receiving treatment with any drugs likely to interact with the study medications, i.e. anticoagulants, cyclosporine, phenytoin, or phenobarbitone. Users of oral contraceptives should be notified that such contraceptive is less reliable if taken with rifampicin; additional (mechanical) contraceptive methods will be discussed with the study participant

 •Patients with HIV co-infection

 •Patients with QTc prolongation > 450 ms on ECG or on other medication known to prolong the QTc interval. In this case, if suspected of BU disease, patients will be offered 8-week rifampicin plus streptomycin therapy

 •Patients unable to take oral medication or having gastrointestinal disease likely to interfere with drug absorption

 •Patients with history or having current clinical signs of ascites, jaundice, myasthenia gravis, renal dysfunction (known or suspected), diabetes mellitus, and severe immune compromise, or evidence of tuberculosis, or leprosy; terminal illness (e.g. metastasized cancer), haematological malignancy, chronic liver disease, abnormal liver function test, and coronary artery disease, or any other condition that would preclude enrolment into the study in the study physician’s opinion

 •Evidence of a clinically significant (as judged by the Investigator) condition or abnormality (other than the indication being studied) that might compromise safety or the interpretation of trial efficacy or safety endpoints

 •Patients with known or suspected bowel strictures who cannot tolerate clarithromycin

 •Patients with a mental health condition that is likely to interfere with compliance with the study protocol in the opinion of the study physician

 •Patients (or parent/legal representative) who are not willing to give informed consent or withdrawal of consent

 •Specific exclusion criteria for the PK sub-study are patients less than 15 years old or less than 40 kg or with renal impairment with a creatinine level higher than the normal one in Benin (7–14 mg/L)

 •Patients who cannot confirm the absence of previous BU treatment or with potential difficulties to be followed up